<DOC>
	<DOC>NCT02864264</DOC>
	<brief_summary>The primary purpose of this study is to determine if single and multiple doses of BMS-986184 are safe and well tolerated in healthy male and female subjects. The primary purpose of the proof of mechanism study is to determine safety and efficacy in patients with ulcerative colitis.</brief_summary>
	<brief_title>Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Female subjects must provide documentation of an acceptable method of surgical sterilization or meet the protocol criteria for menopause Male and female healthy participants, as determined by no evidence of organ dysfunction or any clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory and procedure determinations beyond what is consistent in the target population. Any bacterial, fungal or viral infection, including tuberculosis, HIV, hepatitis B or hepatitis C Subjects with history of any type of heart disease, heart irregularities, high blood pressure, low blood pressure, fainting, ECG abnormalities, or any heart disease from childhood Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>